{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:13:33Z","timestamp":1761182013147,"version":"build-2065373602"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-dose chemotherapy (HDCT) combined with autologous stem cell transplantation (ASCT) rescue is an effective treatment option for relapsed or refractory germ-cell tumors. The TI-CE regimen, consisting of paclitaxel and ifosfamide for stem cell mobilization followed by high dose carboplatin and etoposide with ASCT rescue, is frequently used in the treatment of refractory disease. This regimen is challenging in patients who have undergone unilateral nephrectomy, since potential nephrotoxicity of ifosfamide poses a serious risk for permanent damage of the preserved kidney. Currently, the literature lacks data on the substitution of ifosfamide in the TI-CE regimen for an alternative chemotherapeutic agent with equivalent potency while being less nephrotoxic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a case of a patient with refractory progressive metastatic germ-cell tumor who underwent nephrectomy and was successfully treated with a modified chemo-mobilization strategy. In the TI-CE protocol, ifosfamide was replaced for cyclophosphamide (TC-CE), resulting in a sufficient stem cell harvest through a single apheresis session. Post chemo-mobilization, LDH and hCG\u2009+\u2009hCG\u03b2 levels were normalized. Renal function remained stable throughout the course of treatment. Two months after HDCT, the patient showed a complete metabolic response, with no detectable tumor remnants. Currently, one year post-therapy, there are no signs of disease recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An effective and potentially less nephrotoxic chemo-mobilization regimen, using paclitaxel and cyclophosphamide (TC-CE), was administered to a patient with refractory metastatic germ-cell tumor who underwent HDCT followed by ASCT rescue after unilateral nephrectomy. Cyclophosphamide demonstrated to be a viable substitute for ifosfamide within the TI-CE regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-025-04818-0","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:42:38Z","timestamp":1761154958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy\u2014A case report"],"prefix":"10.1007","volume":"95","author":[{"given":"Lotte M. G.","family":"Hulskotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loek A. W.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Sijm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Desar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minke","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"4818_CR1","unstructured":"Laguna MP, Albers P, Algaba F, Bokemeyer C, Boormans JL, di Nardo D, Fischer S, Fizazi K, Gremmels H, Le\u00e3o R, Nicol D, Nicolai N, Oldenburg J T, Tandstad. EAU guideline on testicular cancer \u2013 limited update april 2024. ISBN 978-94-92671-23-3. EAU Guidelines Office, Arnhem, The Netherlands"},{"issue":"26","key":"4818_CR2","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1200\/JCO.23.02542","volume":"42","author":"JP Gleeson","year":"2024","unstructured":"Gleeson JP, Knezevic A, Bromberg M, Patil S, Sheinfeld J, Carver BS, Bains M, Jones DR, Bajorin DF, Bosl GJ, McHugh DJ, Funt SA, Motzer RJ, Feldman DR (2024) Paclitaxel, Ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: long-term follow-up and outcomes for favorable- and unfavorable-risk disease. J Clin Oncol 42(26):3130\u20133139. https:\/\/doi.org\/10.1200\/JCO.23.02542","journal-title":"J Clin Oncol"},{"issue":"10","key":"4818_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","volume":"28","author":"DR Feldman","year":"2010","unstructured":"Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ (2010) TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 28(10):1706\u20131713. https:\/\/doi.org\/10.1200\/JCO.2009.25.1561","journal-title":"J Clin Oncol"},{"issue":"7","key":"4818_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1586\/era.10.231","volume":"11","author":"MH Voss","year":"2011","unstructured":"Voss MH, Feldman DR, Motzer RJ (2011) High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther 11(7):1093\u20131105. https:\/\/doi.org\/10.1586\/era.10.231","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1\u20132","key":"4818_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14737140.2023.2290196","volume":"24","author":"JE Quiroz-Aldave","year":"2024","unstructured":"Quiroz-Aldave JE, Durand-V\u00e1squez MDC, Ch\u00e1vez-V\u00e1squez FS, Rodr\u00edguez-Angulo AN, Gonz\u00e1les-Salda\u00f1a SE, Alcalde-Loyola CC, Coronado-Arroyo JC, Zavaleta-Guti\u00e9rrez FE, Concepci\u00f3n-Urteaga LA, Haro-Varas JC, Concepci\u00f3n-Zavaleta MJ (2024) Ifosfamide-induced nephrotoxicity in oncological patients. Expert Rev Anticancer Ther 24(1\u20132):5\u201314. https:\/\/doi.org\/10.1080\/14737140.2023.2290196","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"4818_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5306\/wjco.v11.i4.190","volume":"11","author":"MLC Santos","year":"2020","unstructured":"Santos MLC, de Brito BB, da Silva FAF, Botelho ACDS, de Melo FF (2020) Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol 11(4):190\u2013204. https:\/\/doi.org\/10.5306\/wjco.v11.i4.190","journal-title":"World J Clin Oncol"},{"issue":"5","key":"4818_CR7","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.esmoop.2024.103449","volume":"9","author":"C Seidel","year":"2024","unstructured":"Seidel C, Schaefers C, Connolly EA, Weickhardt A, Grimison P, Wong V, De Giorgi U, Hentrich M, Zsch\u00e4bitz S, Ochsenreither S, Vincenzi B, Oing C, Bokemeyer C, Engel N, Alsdorf W, Tran B (2024) Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis. ESMO Open 9(5):103449. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103449","journal-title":"ESMO Open"},{"issue":"5","key":"4818_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105081","volume":"10","author":"A Chehrazi-Raffle","year":"2025","unstructured":"Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M (2025) Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open 10(5):105081. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105081","journal-title":"ESMO Open"},{"issue":"11","key":"4818_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","volume":"44","author":"ME De Jonge","year":"2005","unstructured":"De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44(11):1135\u20131164. https:\/\/doi.org\/10.2165\/00003088-200544110-00003","journal-title":"Clin Pharmacokinet"},{"key":"4818_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8461","author":"S Culine","year":"2008","unstructured":"Culine S, Kramar A, Th\u00e9odore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, H\u00e9ron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP (2008) Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Randomized trial comparing bleomycin\/etoposide\/cisplatin with alternating cisplatin\/cyclophosphamide\/doxorubicin and vinblastine\/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26(3):421\u2013427. https:\/\/doi.org\/10.1200\/JCO.2007.13.8461"},{"issue":"2","key":"4818_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0002-9343(86)90255-x","volume":"81","author":"CJ Logothetis","year":"1986","unstructured":"Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A (1986) Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 81(2):219\u2013228. https:\/\/doi.org\/10.1016\/0002-9343(86)90255-x","journal-title":"Am J Med"},{"issue":"2","key":"4818_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/00000421-199704000-00017","volume":"20","author":"S Culine","year":"1997","unstructured":"Culine S, Th\u00e9odore C, Bekradda M, Farhat F, Terrier-Lacombe MJ, Droz JP (1997) Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))\/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 20(2):184\u2013188. https:\/\/doi.org\/10.1097\/00000421-199704000-00017","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"4818_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jca.21360","volume":"30","author":"SA Tuchman","year":"2015","unstructured":"Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, Chute JP, Sullivan K, Morris Engemann A, Yopp A, Li Z, Corbet K, Chao N, Gasparetto C (2015) Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher 30(3):176\u2013182. https:\/\/doi.org\/10.1002\/jca.21360","journal-title":"J Clin Apher"},{"issue":"3","key":"4818_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.eururo.2006.10.035","volume":"51","author":"JP Droz","year":"2007","unstructured":"Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, P\u00e9ny J, Cur\u00e9 H, Chevreau C, Th\u00e9odore C, Bouzy J, Culine S, Genito-Urinary Group of the French Federation of Cancer Centers (GETUG) (2007) Failure of high-dose cyclophosphamide and Etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 51(3):739\u2013746 discussion 747-8. https:\/\/doi.org\/10.1016\/j.eururo.2006.10.035","journal-title":"Eur Urol"},{"issue":"16","key":"4818_CR15","first-page":"3730","volume":"53","author":"RJ Motzer","year":"1993","unstructured":"Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bosl GJ (1993) Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53(16):3730\u20133735","journal-title":"Cancer Res"},{"key":"4818_CR16","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1200\/JCO.2006.09.2148","volume":"25","author":"A Lorch","year":"2007","unstructured":"Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Oliver Rick O (2007) Single versus Sequential; High-Dose chemotherapy in patients with relapsed or refractory germ cell tumors: A prospective randomized multicenter trial of the german testicular cancer study group. JCO 25:2778\u20132784. https:\/\/doi.org\/10.1200\/JCO.2006.09.2148","journal-title":"JCO"},{"issue":"2","key":"4818_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7326\/0003-4819-117-2-124","volume":"117","author":"ER Broun","year":"1992","unstructured":"Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, Tricot GJ (1992) Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117(2):124\u2013128. https:\/\/doi.org\/10.7326\/0003-4819-117-2-124","journal-title":"Ann Intern Med"},{"issue":"6","key":"4818_CR18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.1994.12.6.1223","volume":"12","author":"W Siegert","year":"1994","unstructured":"Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D (1994) High-dose treatment with carboplatin, etoposide, and Ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I\/II study. The German testicular cancer cooperative study group. J Clin Oncol 12(6):1223\u20131231. https:\/\/doi.org\/10.1200\/JCO.1994.12.6.1223","journal-title":"J Clin Oncol"},{"issue":"3","key":"4818_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2006.09.006","volume":"61","author":"J Spratlin","year":"2007","unstructured":"Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61(3):222\u2013229. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.09.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1 Suppl","key":"4818_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D","volume":"67","author":"ML Slevin","year":"1991","unstructured":"Slevin ML (1991) The clinical pharmacology of etoposide. Cancer 67(1 Suppl):319\u2013329. https:\/\/doi.org\/10.1002\/1097-0142(19910101)67:1+%3C319::AID-CNCR2820671319%3E3.0.CO;2-D","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04818-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:42:39Z","timestamp":1761154959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04818-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4818"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04818-0","relation":{"references":[{"id-type":"doi","id":"10.1200\/JCO.2007.13.8461","asserted-by":"subject"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the patient for publication of the details of his medical case. The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"103"}}